Skip to main content

Apollomics Inc.

corporate_fare Company Profile

Apollomics Inc.

APLM·NASDAQ·Life Sciences·CIK 0001944885

Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer treatments. The company's approach involves harnessing the immune system and targeting specific molecular pathways to inhibit cancer growth. Its product portfolio includes Vebreltinib (APL-101), an oral, highly selective c-Met inhibitor currently in Phase 2 clinical trials for non-small cell lung cancer and other solid tumors with MET dysregulation. APL-102, an oral small molecule multiple tyrosine kinase inhibitor, is in a Phase 1 clinical trial to inhibit various kinases activated in cancer cells. Additionally, APL-122 is a tumor inhibitor candidate targeting ErbB1/2/4 signaling pathways, which is in Phase 1 dose escalation clinical trials for treating brain cancers. The company also has immuno-oncology product candidates, including APL-501, APL-502, and APL-801. Apollomics, Inc. was founded in 2015 and is based in Foster City, California.

Apollomics Inc. (NASDAQ:APLM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for APLM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for APLM spans 6-K, 4, SCHEDULE 13D/A, 20-F.

Recent high-impact activity:

  • Apollomics Posts $8.8M H1 Loss With Just $1.0M Cash on Hand
  • Apollomics H1 2026: Going-Concern Warning With Only $1.0M Cash
  • CFO Invests $400K in Private Placement, Boosting Insider Confidence
  • CEO Chen Acquires 536,667 Shares in $5.55M PIPE, Boosting Stake to 49.76%
  • $10M Private Placement Priced at $15/Share, Insiders Participate

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$8.5M
Net Income
-$10.94M
Diluted EPS
-$7.57
Op. Cash Flow
-$10.37M
Cash & Equivalents
$3.28M
Debt / Equity
0.00×
Net Margin
-128.7%
Source: 20-F · filed 2026-04-24 · accession 0001193125-26-177357

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 5,402 shares in APLM as of the October 30, 2026 settlement, a 0.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 3.2% of APLM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,402 shares as of October 30, 2026
Change vs prior period▲ 0.1%
Days to cover1.00 at avg daily volume of 22,107
Daily short volume (FINRA facilities)3.2% of 1,924 shares on November 20, 2026
5-day average short volume16.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

APLM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$15.54 -6.92% today
52-week range · as of 2026-11-06 $10.01 – $31
Market cap
$45.28M
Volume
4.1K (0.3× avg)
3-mo avg 15.1K
Live data · 2026-11-21 11:21 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed APLM - Latest Insights

APLM
Nov 09, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.25
Real-time Price: $15.54 info
Change: -$2.72 (-15%) info
Market Cap: $45.284M info
APLM
Nov 06, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $19.00
Real-time Price: $15.54 info
Change: -$3.47 (-18%) info
Market Cap: $45.284M info
APLM
Aug 17, 2026, 7:23 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $23.55
Real-time Price: $15.54 info
Change: -$8.02 (-34%) info
Market Cap: $45.284M info
APLM
Aug 17, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.55
Real-time Price: $15.54 info
Change: -$8.02 (-34%) info
Market Cap: $45.284M info
APLM
Aug 11, 2026, 4:35 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.16
Real-time Price: $15.54 info
Change: -$2.63 (-14%) info
Market Cap: $45.284M info
APLM
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.95
Real-time Price: $15.54 info
Change: -$3.41 (-18%) info
Market Cap: $45.284M info
APLM
Jun 24, 2026, 6:28 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $20.50
Real-time Price: $15.54 info
Change: -$4.97 (-24%) info
Market Cap: $45.284M info
APLM
Jun 24, 2026, 5:11 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $20.50
Real-time Price: $15.54 info
Change: -$4.97 (-24%) info
Market Cap: $45.284M info
APLM
Apr 27, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.28
Real-time Price: $15.54 info
Change: +$2.25 (+17%) info
Market Cap: $45.284M info
APLM
Apr 24, 2026, 4:24 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $13.28
Real-time Price: $15.54 info
Change: +$2.25 (+17%) info
Market Cap: $45.284M info
APLM
Apr 08, 2026, 7:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $15.40
Real-time Price: $15.54 info
Change: +$0.135 (+0.88%) info
Market Cap: $45.284M info
APLM
Apr 01, 2026, 4:52 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $14.72
Real-time Price: $15.54 info
Change: +$0.815 (+6%) info
Market Cap: $45.284M info
APLM
Mar 09, 2026, 5:16 PM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $20.01
Real-time Price: $15.54 info
Change: -$4.48 (-22%) info
Market Cap: $45.284M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets